Abu Dhabi Opens Strategic Life Sciences Corridor to California Through Biocom Partnership

ABU DHABI, UAE — The Department of Health – Abu Dhabi (DoH) and Biocom California on June 23, 2026 announced a strategic partnership designed to create a formal gateway between Abu Dhabi’s life sciences ecosystem and California’s biotech cluster. The memorandum of understanding links Biocom, which represents more than 1,800 biotechnology, pharmaceutical and medical technology organisations, with Abu Dhabi’s Health, Endurance, Longevity and Medicine (HELM) Cluster to enable cross-border collaboration on research, investment and commercialisation.

"The most successful life sciences ecosystems are those that can connect talent, research, investment and implementation across borders," said H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of DoH. "Through this partnership with Biocom, we are creating a direct bridge between Abu Dhabi's intelligent life sciences ecosystem and one of the world's leading centres of life sciences innovation. For innovators, researchers, and investors, this creates new opportunities to access Abu Dhabi's living lab for intelligent life sciences, where scientific discoveries can be translated into real-world impact faster and at scale."

What the agreement covers

The partnership sets out an exchange of expertise on ecosystem and cluster development, including industry best practices, sector policy insights and lessons learned. It aims to strengthen connectivity between innovators, researchers, investors and entrepreneurs in both markets and to accelerate development, validation and scaling of next-generation health solutions.

• Market access: Biocom members in California will gain pathways to Abu Dhabi’s intelligent life sciences ecosystem and its living lab model, enabling in-region testing and real-world implementation.
• Knowledge exchange: Both parties will share policy insights and cluster-development best practices to bolster local innovation environments.
• Commercial collaboration: The MOU will open opportunities for joint events, partner-finding and direct cooperation between companies in California and Abu Dhabi.

Details and stakeholders

Biocom California, described in the agreement as one of the world’s largest life sciences associations, will leverage its network to connect US-based biotechnology, pharmaceutical and medical technology leaders with Abu Dhabi’s HELM Cluster. Joe Panetta, President Emeritus of Biocom, said: "Biocom is honored to be partnering with the DoH under this important MOU. Abu Dhabi life science ecosystem is strategically focused and well supported for the creation of promising new and innovative life science therapies. Biocom reaches out actively to develop a network of partnerships in established and growing life science ecosystems around the world. Under this MOU we look forward to cooperating jointly in events, providing opportunities to find partners for companies in both California and Abu Dhabi and connecting Abu Dhabi to our other partners."

The announcement emphasises Abu Dhabi’s “living lab” approach—bringing discovery, validation and real-world implementation together within a single environment. That model is intended to reduce friction between early-stage innovation and scaled deployment, offering companies the chance to build, test and scale innovations across both the UAE and US markets.

Outlook

Officials say the collaboration will accelerate high-value life sciences activity in both regions by improving cross-border flows of talent, capital and clinical validation. Near-term outcomes are expected to include joint programming, ecosystem development workshops, and facilitated introductions between investors and startups. Over the medium term, the MOU could lead to co-developed projects that leverage Abu Dhabi’s living lab and California’s dense investor and research networks to validate and commercialise therapies and health technologies at scale.